• HP Health Solutions Germany GmbH
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • Phone: +49 (0)89/99 82 07 180
  • Fax: +49 (0)89/99 82 07 188
  • moc.ph@ynamregsnoituloshtlaehph

HP Health Solutions

Dr. Federico Buersgens, Global Head of R&D HP200A and Managing Director HP Health Solutions Germany GmbH
Amanda Brown, Director of Regulatory Affairs and Quality
Dr. Anastasia Liapis, Head of Strategy and Partnerships

About HP Health Solutions

In February 2021, Silicon Valley-based Hewlett Packard acquired 100% of molecular diagnostics start-up GNA Biosolutions. GNA was founded in 2010 and has currently in Martinsried a multidisciplinary team of about 45 people who are fully integrated into HP. The proprietary technology developed by GNA, Pulse Controlled Amplification (PCA), is based on the gold standard molecular technology, the polymerase chain reaction (PCR), but works much faster (minutes instead of hours) and can be used to produce small, portable, energy-efficient instruments ideally suited to provide near-patient diagnosis outside the laboratory.

What is your motivation?

Our multidisciplinary team of biologists, engineers, physicists and developers has created a powerful new technology that can significantly accelerate molecular testing. Our innovations aim to improve patient care, prevent harm, save lives, and enable better molecular diagnostics and DNA analysis. We achieve this by maintaining the effectiveness of our QMS, complying with applicable quality, safety and regulatory standards, and striving for excellence in everything we do.

“From our first steps as a small university spin-off to becoming a subsidiary of a major international corporation, IZB’s location and facilities have provided us with ideal conditions for research and development.”

Dr. Federico Buersgens, former CEO of GNA Biosolutions and now Global Head of R&D HP 200A

GNA was founded in 2010 and currently consists of a multidisciplinary team of 44 people. GNA’s technology, called Pulse Controlled Amplification (PCA), is based on the molecular gold standard technology, the polymerase chain reaction (PCR), but works much faster (minutes instead of hours) and can be used to produce small, portable, energy-efficient instruments. Unlike traditional PCR, PCA enables the production of systems that can provide a diagnosis close to the patient outside the laboratory. The company is currently focusing on the development of a rapid diagnostic system and assays to diagnose Covid-19, which can diagnose up to eight patient samples simultaneously and can be used in many environments, including airports and other transit points.